BACKGROUND: Although rapid on-site cytologic evaluation (ROSE) is widely used during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), its role remains unclear. OBJECTIVES: The purpose of the present study was to evaluate the efficacy of ROSE during EBUS-TBNA in the diagnosis of lung cancer. METHODS:One hundred and twenty patients highly suspected of having lung cancer who had hilar/mediastinal lymphadenopathy or a tumor adjacent to the central airway were enrolled in this study and randomized to undergo EBUS-TBNA with or without ROSE. RESULTS:Twelve patients with visible endobronchial lesions were excluded in the analysis. Thus, a total of 108 patients (55 in the ROSE group, 53 in the non-ROSE group) were analyzed. Additional procedures including EBUS-TBNA for lesions other than the main target lesion and/or transbronchial biopsy in the same setting were performed in 11% of patients in the ROSE group and 57% in the non-ROSE group (p < 0.001). Mean puncture number was significantly lower in the ROSE group (2.2 vs. 3.1 punctures, p < 0.001), and mean bronchoscopy time was similar between both groups (22.3 vs. 22.1 min, p = 0.95). The sensitivity and accuracy for diagnosing lung cancer were 88 and 89% in the ROSE group, and 86 and 89% in the non-ROSE group, respectively. No complications were associated with the procedures. CONCLUSIONS:ROSE during EBUS-TBNA is associated with a significantly lower need for additional bronchoscopic procedures and puncture number.
RCT Entities:
BACKGROUND: Although rapid on-site cytologic evaluation (ROSE) is widely used during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), its role remains unclear. OBJECTIVES: The purpose of the present study was to evaluate the efficacy of ROSE during EBUS-TBNA in the diagnosis of lung cancer. METHODS: One hundred and twenty patients highly suspected of having lung cancer who had hilar/mediastinal lymphadenopathy or a tumor adjacent to the central airway were enrolled in this study and randomized to undergo EBUS-TBNA with or without ROSE. RESULTS: Twelve patients with visible endobronchial lesions were excluded in the analysis. Thus, a total of 108 patients (55 in the ROSE group, 53 in the non-ROSE group) were analyzed. Additional procedures including EBUS-TBNA for lesions other than the main target lesion and/or transbronchial biopsy in the same setting were performed in 11% of patients in the ROSE group and 57% in the non-ROSE group (p < 0.001). Mean puncture number was significantly lower in the ROSE group (2.2 vs. 3.1 punctures, p < 0.001), and mean bronchoscopy time was similar between both groups (22.3 vs. 22.1 min, p = 0.95). The sensitivity and accuracy for diagnosing lung cancer were 88 and 89% in the ROSE group, and 86 and 89% in the non-ROSE group, respectively. No complications were associated with the procedures. CONCLUSIONS: ROSE during EBUS-TBNA is associated with a significantly lower need for additional bronchoscopic procedures and puncture number.
Authors: Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544
Authors: Daniël A Korevaar; Sara Colella; René Spijker; Patrick M Bossuyt; Lars Konge; Paul Frost Clementsen; Jouke T Annema Journal: Respiration Date: 2016-12-08 Impact factor: 3.580
Authors: Emily Hopkins; David Moffat; Ian Parkinson; Peter Robinson; Hubertus Jersmann; Brendan Dougherty; Mohammed I Birader; Kate Francis; Phan Nguyen Journal: J Thorac Dis Date: 2016-09 Impact factor: 2.895
Authors: Hiren J Mehta; Nichole T Tanner; Gerard Silvestri; Suzanne M Simkovich; Clayton Shamblin; Stephanie R Shaftman; Paul J Nietert; Jack Yang Journal: Cancer Cytopathol Date: 2014-09-03 Impact factor: 5.284